Skip to main content

Farewell letter from Prof. Alexander Tenenbaum, Editor-in-Chief

The close interrelationship between cardiovascular diseases and alterations in glucose metabolism has raised the prospect that atherosclerosis and type 2 diabetes share a common background. Both conditions seem to be based on similar genetic and environmental precursors; this has been termed "common soil" and the American Heart Association explicitly stated in 1999 that "diabetes is a cardiovascular disease".

In this context, in 2001 my friend and colleague Prof. Enrique (Zvi) Fisman and I began to consider the possibility of creating a scientific journal specifically dedicated to cover the intersection between diabetes and cardiovascular disorders. The task did not seem to be easy since it was necessary to establish an Editorial Board, obtain an ISSN (International Standard Serial Number), register the Journal in PubMed and other repositories of medical information, find and appropriate publisher, publicize the existence of the Journal as widely as possible… and we had no idea how to start and accomplish these tasks.

We contacted then BioMed Central (BMC), a United Kingdom-based scientific open access publisher. BMC was then a young and dynamic company, founded in 2000; BMC representatives helped us in each of the initial steps, providing us with guidance and advice. We named the Journal Cardiovascular Diabetology, it was launched on April 2002 and got its first official Journal Impact Factor (JIF) in 2007. BMC is a part of Springer Nature since 2008.

As of January 1, 2022, for personal reasons, I will be compelled to step out of my position as Editor-in-Chief. I have taken this decision with sadness, but at the same time with pride as I look at what has been done during these almost two decades. During this period Cardiovascular Diabetology has raised its JIF in a nearly constant yearly pattern, presenting a 2020 JIF of 9.951, ranking it in the 93.45 JIF percentile in the category “Endocrinology & Metabolism”—being thus the leading open access journal in the field—and in the 90.49 percentile in the category "Cardiac & Cardiovascular Systems” journals. The Journal is offered more articles for publication each year and the number and quality of the published articles grow continuously.

The Journal is currently facing two new challenges. The first is the recruitment of highly qualified Associate Editors, who will help Cardiovascular Diabetology to publish much more articles and in a quick way. The second is the implementation of SNAPP, the new and sophisticated editorial submission system from Springer Nature, that makes articles’ management smoother and more efficient.

None of the above-mentioned achievements would have been possible without the efforts, loyalty and help of countless people. I am aware that the success of our journal is a joint attainment of researchers, authors, readers, Editorial Board members, external reviewers, Journal Development Editors and BMC and Springer Nature scientific and technical teams. I would like to express my gratitude to all of them. It has been an honor and a privilege for me to have been a leading part of this collective initiative.

Thank you.

Author information

Authors and Affiliations



The author read and approved the final manuscript.

Corresponding author

Correspondence to Alexander Tenenbaum.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tenenbaum, A. Farewell letter from Prof. Alexander Tenenbaum, Editor-in-Chief. Cardiovasc Diabetol 20, 233 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: